Home » Stocks » QLGN

Qualigen Therapeutics, Inc. (QLGN)

Stock Price: $1.53 USD -0.13 (-7.83%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 47.86M
Revenue (ttm) 5.70M
Net Income (ttm) -19.94M
Shares Out 17.43M
EPS (ttm) -2.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.53
Previous Close $1.66
Change ($) -0.13
Change (%) -7.83%
Day's Open 1.68
Day's Range 1.51 - 1.73
Day's Volume 673,977
52-Week Range 0.42 - 9.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Qualigen Therapeutics Inc (NASDAQ: QLGN) was one of the sponsors for the Benzinga Biotech Global Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in n...

3 weeks ago - Benzinga

Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are ticking lower as the company withdrew the FDA Emergency Use Authorization (EUA) application for its FastPack SARS-CoV-2 IgG diagnostic test for COVID-...

1 month ago - Benzinga

CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectio...

2 months ago - GlobeNewsWire

CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral di...

2 months ago - GlobeNewsWire

CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral di...

2 months ago - GlobeNewsWire

CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional ...

4 months ago - PRNewsWire

CARLSBAD, Calif., Dec. 16, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single institu...

4 months ago - PRNewsWire

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final formulation and...

5 months ago - PRNewsWire

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that Michael Poirier, President, Chief Executive Officer and Chairman, has issued a letter to Qualige...

6 months ago - PRNewsWire

CARLSBAD, Calif., Aug. 31, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

8 months ago - PRNewsWire

CARLSBAD, Calif., Aug. 28, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

8 months ago - PRNewsWire

Qualigen Therapeutics, Inc. (QLGN) CEO Michael Poirier on Q1 2021 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

CARLSBAD, Calif., Aug. 14, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

8 months ago - PRNewsWire

CARLSBAD, Calif., Aug. 4, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

9 months ago - PRNewsWire

CARLSBAD, Calif., Aug. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

9 months ago - PRNewsWire

CARLSBAD, Calif. , July 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

9 months ago - PRNewsWire

CARLSBAD, Calif., July 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), announced that today Chief Executive Officer Michael Poirier has issued a letter...

10 months ago - PRNewsWire

CARLSBAD, Calif., July 10, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced the closing of its previously announced registered direct offeri...

10 months ago - PRNewsWire

CARLSBAD, Calif., July 8, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single institut...

10 months ago - PRNewsWire

CARLSBAD, Calif., July 7, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company") announces it has engaged Pro Football Hall of Fame and College Football Hall of Fa...

10 months ago - PRNewsWire

Qualigen Therapeutics shares are trading higher on Wednesday, after the company signed an exclusive licensing agreement with the University of Louisville and it plans to develop its AS1411 for the treat...

11 months ago - Benzinga

CARLSBAD, Calif., June 10, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today the signing of an exclusive license agreement with the University of ...

11 months ago - PRNewsWire

About QLGN

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compound... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Andrew Ritter
Employees
34
Stock Exchange
NASDAQ
Ticker Symbol
QLGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for QLGN stock is "Strong Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Strong Buy